JP2016104045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016104045A5 JP2016104045A5 JP2016043151A JP2016043151A JP2016104045A5 JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5 JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- glycoprotein
- seq
- protein comprises
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 claims 11
- 108090000288 Glycoproteins Proteins 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 3
- 238000006011 modification reaction Methods 0.000 claims 3
- 241000699802 Cricetulus griseus Species 0.000 claims 2
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 210000001672 Ovary Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000033581 fucosylation Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Claims (15)
- 改変を有するFXタンパク質を発現する細胞であって、該FXタンパク質は、配列番号1と少なくとも90%同一であるアミノ酸配列を含み、該改変は、位置289のセリンでの置換および位置90のリジンでの置換を含む、細胞。
- 前記FXタンパク質は、配列番号1と少なくとも95%同一であるアミノ酸配列を含む、請求項1に記載の細胞。
- 前記FXタンパク質は、位置289にセリンおよび位置90にリジンを有することを除いて、配列番号1と同一であるアミノ酸を含む、請求項1に記載の細胞。
- 前記FXタンパク質が、配列番号2を含む、請求項1に記載の細胞。
- 前記細胞が、チャイニーズハムスター卵巣(CHO)細胞である、請求項1〜4のいずれか一項に記載の細胞。
- 前記細胞が、糖タンパク質を発現する、請求項1〜5のいずれか一項に記載の細胞。
- 前記糖タンパク質が、抗体である、請求項6に記載の細胞。
- 前記細胞が37℃にて前記糖タンパク質をフコシル化する能力は、前記改変を欠く細胞によって呈される該糖タンパク質をフコシル化する能力の10%以下である、請求項6または7に記載の細胞。
- フコシル化の低下を有する糖タンパク質を作製するための方法であって、該方法は、
(a)請求項1〜4のいずれか一項に記載の細胞を培養する工程であって、該細胞は糖タンパク質を発現する工程、および
(b)該糖タンパク質を該培養物から単離する工程
を含む、方法。 - 前記培養工程は、外部フコース供給源の非存在下で37℃の温度にて前記細胞を培養する工程をさらに含む、請求項9に記載の方法。
- 前記糖タンパク質が、免疫グロブリンCH2領域および免疫グロブリンCH3領域を含む、請求項9または10に記載の方法。
- 前記糖タンパク質が、抗体である、請求項11に記載の方法。
- 前記細胞が、チャイニーズハムスター卵巣(CHO)細胞である、請求項9〜12のいずれか一項に記載の方法。
- 前記糖タンパク質の6%以下がフコシル化される、請求項11に記載の方法。
- 前記糖タンパク質の2%以下がフコシル化される、請求項14に記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18340009P | 2009-06-02 | 2009-06-02 | |
US61/183,400 | 2009-06-02 | ||
US34885810P | 2010-05-27 | 2010-05-27 | |
US61/348,858 | 2010-05-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014251541A Division JP2015051021A (ja) | 2009-06-02 | 2014-12-12 | フコシル化欠損細胞 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016202634A Division JP2017006147A (ja) | 2009-06-02 | 2016-10-14 | フコシル化欠損細胞 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016104045A JP2016104045A (ja) | 2016-06-09 |
JP2016104045A5 true JP2016104045A5 (ja) | 2016-12-01 |
JP6211642B2 JP6211642B2 (ja) | 2017-10-11 |
Family
ID=42338231
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012514045A Active JP5744856B2 (ja) | 2009-06-02 | 2010-06-01 | フコシル化欠損細胞 |
JP2014251541A Withdrawn JP2015051021A (ja) | 2009-06-02 | 2014-12-12 | フコシル化欠損細胞 |
JP2016043151A Active JP6211642B2 (ja) | 2009-06-02 | 2016-03-07 | フコシル化欠損細胞 |
JP2016202634A Pending JP2017006147A (ja) | 2009-06-02 | 2016-10-14 | フコシル化欠損細胞 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012514045A Active JP5744856B2 (ja) | 2009-06-02 | 2010-06-01 | フコシル化欠損細胞 |
JP2014251541A Withdrawn JP2015051021A (ja) | 2009-06-02 | 2014-12-12 | フコシル化欠損細胞 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016202634A Pending JP2017006147A (ja) | 2009-06-02 | 2016-10-14 | フコシル化欠損細胞 |
Country Status (17)
Country | Link |
---|---|
US (8) | US8409838B2 (ja) |
EP (3) | EP2438171B1 (ja) |
JP (4) | JP5744856B2 (ja) |
KR (2) | KR101441437B1 (ja) |
CN (1) | CN102459603B (ja) |
AU (1) | AU2010256753B2 (ja) |
BR (1) | BRPI1010035A2 (ja) |
CA (1) | CA2764370C (ja) |
DK (3) | DK2808393T3 (ja) |
ES (2) | ES2661074T3 (ja) |
HK (3) | HK1163745A1 (ja) |
HU (1) | HUE038596T2 (ja) |
IL (1) | IL216624A (ja) |
PL (3) | PL3279326T3 (ja) |
SG (1) | SG176251A1 (ja) |
TW (1) | TWI513818B (ja) |
WO (1) | WO2010141478A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140161782A1 (en) | 2008-06-09 | 2014-06-12 | Targazyme, Inc. | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase |
KR101441437B1 (ko) | 2009-06-02 | 2014-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 푸코실화-결핍 세포 |
ES2687771T3 (es) | 2011-03-06 | 2018-10-29 | Merck Serono Sa | Líneas de células con bajo nivel de fucosa y sus usos |
WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
EP2722673B1 (en) | 2012-10-17 | 2017-07-12 | Hexal AG | Improved method of mapping glycans of glycoproteins |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
US20150093782A1 (en) * | 2013-10-01 | 2015-04-02 | The University Of Wyoming | Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins |
HUE045307T2 (hu) | 2014-03-11 | 2019-12-30 | Regeneron Pharma | EGFRVIII-ellenes antitestek és alkalmazásaik |
KR20170012286A (ko) * | 2014-05-30 | 2017-02-02 | 뉴 잉글랜드 바이오랩스, 인크 | 탈당화 시약 및 방법 |
SG11201610699XA (en) * | 2014-07-07 | 2017-01-27 | Targazyme Inc | Manufacture and cryopreservation of fucosylated cells for therapeutic use |
CN105671109B (zh) * | 2014-11-20 | 2019-08-23 | 中国人民解放军军事医学科学院生物工程研究所 | 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法 |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017079165A1 (en) * | 2015-11-02 | 2017-05-11 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
CA3010598A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Modulation of afucosylated species in a monoclonal antibody composition |
EP3411401A1 (en) | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
KR20180134894A (ko) | 2016-04-20 | 2018-12-19 | 리제너론 파마슈티칼스 인코포레이티드 | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 |
BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
EP3339444A1 (en) * | 2016-12-20 | 2018-06-27 | Mabxience Research, S.L. | Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans |
CA3110254C (en) * | 2018-08-29 | 2023-08-29 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
KR20210084488A (ko) | 2018-10-29 | 2021-07-07 | 가부시키가이샤 멘에키세이부츠 켄큐죠 | 항hiv항체 및 그 제조 방법 |
JP2023527352A (ja) | 2020-05-26 | 2023-06-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片 |
CN116057069A (zh) | 2020-06-03 | 2023-05-02 | 瑞泽恩制药公司 | 用抗SARS-CoV-2刺突糖蛋白抗体治疗或预防SARS-CoV-2感染和COVID-19的方法 |
CN112843234B (zh) * | 2021-01-20 | 2022-09-06 | 四川大学华西第二医院 | 一种调控生物机体内gdp-甘露糖的浓度的装置 |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
EP4359440A1 (en) | 2021-06-22 | 2024-05-01 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibody drug conjugates and uses thereof |
WO2023287875A1 (en) | 2021-07-14 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
US20240010737A1 (en) | 2022-03-02 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1914244E (pt) * | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
JP2001145488A (ja) | 1999-11-19 | 2001-05-29 | Natl Inst Of Advanced Industrial Science & Technology Meti | シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子 |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
CA2785941C (en) * | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US20020150968A1 (en) | 2001-01-10 | 2002-10-17 | Wang Peng G. | Glycoconjugate and sugar nucleotide synthesis using solid supports |
DE60211329T2 (de) | 2001-01-16 | 2007-05-24 | Regeneron Pharmaceuticals, Inc. | Isolierung von sezernierte proteine exprimierenden zellen |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
KR100585140B1 (ko) | 2004-04-26 | 2006-05-30 | 삼성전자주식회사 | 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법 |
US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
EP1888638A2 (en) | 2005-06-03 | 2008-02-20 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
SI2059536T1 (sl) | 2006-08-14 | 2014-06-30 | Xencor, Inc. | Optimirana protitelesa, ki ciljajo CD19 |
US20100028951A1 (en) | 2007-03-07 | 2010-02-04 | Stephen Hamilton | Production of glycoproteins with modified fucosylation |
EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
JP5662149B2 (ja) | 2008-08-13 | 2015-01-28 | 協和発酵キリン株式会社 | 遺伝子組換えプロテインs組成物 |
KR101441437B1 (ko) | 2009-06-02 | 2014-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 푸코실화-결핍 세포 |
ES2687771T3 (es) | 2011-03-06 | 2018-10-29 | Merck Serono Sa | Líneas de células con bajo nivel de fucosa y sus usos |
-
2010
- 2010-06-01 KR KR1020117031320A patent/KR101441437B1/ko active IP Right Grant
- 2010-06-01 DK DK14179885.0T patent/DK2808393T3/en active
- 2010-06-01 CA CA2764370A patent/CA2764370C/en active Active
- 2010-06-01 ES ES14179885.0T patent/ES2661074T3/es active Active
- 2010-06-01 US US12/791,637 patent/US8409838B2/en active Active
- 2010-06-01 EP EP10721096.5A patent/EP2438171B1/en active Active
- 2010-06-01 BR BRPI1010035-0A patent/BRPI1010035A2/pt not_active Application Discontinuation
- 2010-06-01 DK DK17192430.1T patent/DK3279326T3/da active
- 2010-06-01 HU HUE14179885A patent/HUE038596T2/hu unknown
- 2010-06-01 JP JP2012514045A patent/JP5744856B2/ja active Active
- 2010-06-01 DK DK10721096.5T patent/DK2438171T3/en active
- 2010-06-01 ES ES10721096.5T patent/ES2527173T3/es active Active
- 2010-06-01 EP EP17192430.1A patent/EP3279326B1/en active Active
- 2010-06-01 SG SG2011087517A patent/SG176251A1/en unknown
- 2010-06-01 PL PL17192430T patent/PL3279326T3/pl unknown
- 2010-06-01 PL PL10721096T patent/PL2438171T3/pl unknown
- 2010-06-01 PL PL14179885T patent/PL2808393T3/pl unknown
- 2010-06-01 AU AU2010256753A patent/AU2010256753B2/en active Active
- 2010-06-01 EP EP14179885.0A patent/EP2808393B1/en active Active
- 2010-06-01 CN CN2010800294912A patent/CN102459603B/zh active Active
- 2010-06-01 WO PCT/US2010/036914 patent/WO2010141478A1/en active Application Filing
- 2010-06-01 TW TW099117652A patent/TWI513818B/zh active
- 2010-06-01 KR KR1020147007025A patent/KR101641526B1/ko active IP Right Grant
-
2011
- 2011-11-27 IL IL216624A patent/IL216624A/en active IP Right Grant
-
2012
- 2012-05-07 HK HK12104409.3A patent/HK1163745A1/xx unknown
- 2012-05-07 HK HK14112533.3A patent/HK1198180A1/xx unknown
-
2013
- 2013-02-28 US US13/779,952 patent/US9206455B2/en active Active
-
2014
- 2014-12-12 JP JP2014251541A patent/JP2015051021A/ja not_active Withdrawn
-
2015
- 2015-12-08 US US14/963,178 patent/US9550823B2/en active Active
-
2016
- 2016-03-07 JP JP2016043151A patent/JP6211642B2/ja active Active
- 2016-10-14 JP JP2016202634A patent/JP2017006147A/ja active Pending
- 2016-12-14 US US15/378,670 patent/US10006070B2/en active Active
-
2018
- 2018-05-23 US US15/987,286 patent/US20190024129A1/en not_active Abandoned
- 2018-07-12 HK HK18109072.2A patent/HK1249547A1/zh unknown
-
2019
- 2019-08-30 US US16/556,334 patent/US20200080124A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,255 patent/US11560550B2/en active Active
-
2022
- 2022-12-15 US US18/066,303 patent/US20230295583A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016104045A5 (ja) | ||
AR120511A2 (es) | Producción de proteínas heteromultiméricas | |
BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
JP2019505164A5 (ja) | ||
MY189819A (en) | Genetically modified cells and uses thereof | |
BR112018008648A2 (pt) | métodos de geração de células t a partir de células tronco e métodos imunoterapêuticos ao usar células t | |
MX2019008417A (es) | Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas. | |
AR096839A1 (es) | Proceso mejorado para la producción de anticuerpos monoclonales | |
GB201003701D0 (en) | System for the expression of a protein | |
JP2017505620A5 (ja) | ||
MX2019010575A (es) | Metodo para producir anticuerpos multiespecificos. | |
JP2015532096A5 (ja) | ||
EA202091349A1 (ru) | Способы культивирования клеток | |
MX2015011781A (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
PL439807A1 (pl) | Sposoby oczyszczania przeciwciał i ich kompozycje | |
RU2015129656A (ru) | Гуманизированное моноклональное антитело, специфичное к синдекану-1 | |
BR112016028538A2 (pt) | processo de produção de proteína glicosilada, processos de produção de proteína de fusão e anticorpo monoclonal e fragmento do mesmo, processo de produção de proteína de fusão tnfr-fc, proteína de fusão ou anticorpo monoclonal e fragmento do mesmo | |
BR112016023980A2 (pt) | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) | |
WO2012173344A3 (ko) | Csp-b 5'-sar 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법 | |
MX2019007924A (es) | Vacunas contra la influenza. | |
SG11201902998SA (en) | PROMOTER OF Hspa5 GENE | |
JP2016512251A5 (ja) | ||
MX2022008298A (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
BR112017017303B8 (pt) | Método para obtenção de clones de células de alta produtividade | |
JP2015536347A5 (ja) |